Apex, NC Plant Receives FDA Warning Letter for cGMP Violations
FDA delivered a warning letter to Choice All Natural, Inc., also known as Om Botanical, for major cGMP violations for finished pharmaceuticals. The letter was dated Oct. 24, 2024, and followed an FDA audit of Choice Natural’s manufacturing plant in Apex, North Carolina. The FDA warning letter stated that Choice All Natural isn’t registered with […]
Read More »Category : News
North Carolina Thermo Fisher Plant Gets 483 For Contamination and Air Bubble Problems
Thermo Fisher Scientific makes many important, popular pharmaceuticals for the US market, such as Wegovy, an obesity drug, and Beyfortus, a product that treats infant respiratory syncytial virus. However, FDA recently inspected the firm’s plant in Greenville, NC, and found several issues. FDA inspected Thermo Fisher’s 1.5 million square foot facility run by its Patheon […]
Read More »Category : News
FDA Representative Predicts More Onsite Inspections, Reveals Current Warning Letter Trends
According to an official from the Center of Drug Evaluation and Research (CDER), the FDA’s manufacturing quality staff focuses on two areas: stopping diethylene glycol (DEG) or ethylene glycol (EG) contaminants from entering pharmaceuticals and ensuring that companies making ophthalmic drugs correctly test sterile products. Francis Godwin, director of the Office of Manufacturing Quality at […]
Read More »Category : News
India’s Zydus Hit With FDA Warning Letter
Zydus Lifesciences has been under intense FDA scrutiny in recent months, and received a warning letter for the Indian drugmaker’s production plant in Jarod in July 2024. Earlier in 2024, Zydus received two FDA 483s in a month after FDA inspections of two manufacturing sites in India. At that time, FDA stated the plants had […]
Read More »Category : News
FDA Finalizes cGMP Guidance for ANDA Facilities
In July, FDA outlined details on how it will assign a goal date according to a drug facility’s readiness for inspection. These rules include information for generic drug makers on how they can determine when drug plants associated with an application will be ready for an FDA audit in support of an ANDA or abbreviated […]
Read More »Category : News
EyePoint Receives FDA Warning Letter For cGMP Shortfalls Related To Eye Implant
Ophthalmology manufacturer EyePoint Pharmaceuticals received an FDA warning letter in July for its facility in Watertown, MA, according to the FDA website. EyePoint received an FDA 483 in February, which the company responded to in early March 2024. The FDA violations, which were found in the February audit, included poorly written procedures, batch discrepancies, and […]
Read More »Category : News
FDA Sends Warning Letter To Surgical Robot Maker Globus
FDA delivered a warning letter to Globus Medical in August 2024 for not following quality system regulations and medical device reporting requirements. The FDA warning letter also stated that the firm’s CAPA procedures were not properly addressed regarding quality problems, including Globus Medical’s analysis of reports of missing surgical screws. FDA sent the warning letter […]
Read More »Category : News
FDA Sends Warning Letters To Chinese Syringe Manufacturer
FDA sent warning letters Jiangsu Shenli and Jiangsu Caina in China in July 2024 regardings its practices in manufacturing plastic syringes. In April, the FDA also issued an import alert to both sites. FDA recently published the warning letters that show the agency conducted an FDA inspection of Jiangsu Shenli and Jiangsu Caina about the […]
Read More »Category : News
FDA Hits Aurobindo With OAI 483
FDA hit Indian drugmaker Aurobindo and its Eugia unit with an Official Action Indicated (OAI) 483 after a manufacturing plant inspection at the Bhiwadi facility in April 2024. OAI is the most serious of three FDA audit recommendations, and after the company announced the 483, it said that it is committed to partner with the […]
Read More »Category : News
FDA Reams Out Indian CDMO Brassica for Falsifying Data and Bad Hygiene
Indian CDMO was heavily criticized by FDA in a recent warning letter for falsifying data, doing aseptic processing with dirty and torn gowns, and more. The FDA warning letter to Brassica Pharma was essentially a not-to-do list when an FDA inspector comes for a visit. After the FDA inspected the firm’s Tarapur manufacturing facility in […]
Read More »Category : News
